Clinical Trials Logo
  1. Home
  2. Chronic Urticaria
  3. NCT06268470
  4. Details
NCT06268470 Clinical Trial

Antiplatelet Therapy in Chronic Urticaria

Chronic Urticaria Clinical Trial

Official title:
Efficacy of Antiplatelet Therapy for the Treatment of Chronic Recalcitrant Urticaria

Clinical Trial Details — Status: Active, not recruiting

Administrative data
NCT number NCT06268470
Other study ID # Chula-ARC 001/18
Secondary ID
Status Active, not recruiting
Phase Phase 2
First received
Last updated
Start date June 1, 2018
Est. completion date May 1, 2024

Study information
Verified date February 2024
Source Chulalongkorn University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study compares the combination of antiplatelets and antihistamine versus antihistamine alone for the treatment of chronic spontaneous urticaria

Description:

This study is a randomized control trial comparing the effectiveness of the combination of antiplatelets and antihistamine and antihistamine alone for the treatment of chronic spontaneous urticaria

Recruitment information / eligibility
Status Active, not recruiting
Enrollment 12
Est. completion date May 1, 2024
Est. primary completion date March 1, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: Chronic spontaneous urticaria D-dimer levels over 500 ng/ml Not respond to a conventional dose of antihistamine Exclusion Criteria: Are taking aspirin Have bleeding tendency Have concurrent severe medical illnesses -

Study Design

Related Conditions & MeSH terms

Intervention

Drug:
• Desloratadine plus cilostazol and dipyridamole
Desloratadine 20 mg/day plus cilostazol 150 mg/day and dipyridamole 50 mg/day
• Desloratadine
Desloratadine 20 mg/day

Locations
Country Name City State
Thailand Faculty of Medicine, Chulalongkorn University Bangkok

Sponsors (1)
Lead Sponsor Collaborator
Chulalongkorn University

Country where clinical trial is conducted

Thailand, 

Outcome
Type Measure Description Time frame Safety issue
Primary Weekly urticaria activity score Urticaria activity score over 7 days (UAS7): scores 0-42 from mild to severe 4 weeks
Secondary D-dimer levels D-dimer levels 4 weeks
See also
  Status Clinical Trial Phase
Completed NCT02435238 - AWARE - Chronic Urticaria N/A
Not yet recruiting NCT05513079 - Positive Psychotherapy-Based Counseling (PPT) N/A
Terminated NCT02047136 - Dietary Treatment for Chronic Urticaria N/A
Completed NCT01803763 - Prospective Double-blind Placebo-controlled Study of the Effect of Xolair (Omalizumab) in Chronic Urticaria Patients Phase 2/Phase 3
Terminated NCT01170949 - Efficacy and Safety of Miltefosine in Antihistamine Resistant Chronic Urticaria Phase 2
Completed NCT00598611 - Effects of 5 mg vs. 20 mg Desloratadine on Skin Lesions in Patients With Chronic Urticaria (CU) Phase 3
Completed NCT01610128 - Development of an Urticaria Control Test N/A
Completed NCT02285023 - The Validity, Reliability and Interpretability of Thai-version of Chronic Urticaria Quality of Life Questionnaire
Completed NCT02285049 - Cross-Cultural of the Validity, Reliability and Interpretability of Thai-version of Urticaria Control Test N/A
Completed NCT01715740 - Study of the Effects of Chinese Herbal Medicine on Chronic Urticaria Phase 3
Completed NCT01960283 - Methotrexate in the Treatment of Chronic Idiopathic Urticaria Phase 3
Completed NCT00481676 - Efficacy and Safety of Omalizumab in Adults (18-70 Years) With Moderate to Severe Chronic Urticaria Phase 2
Completed NCT01713725 - Efficacy and Safety Study of Omalizumab (Xolair®) to Treat Chronic Urticaria Phase 2
Completed NCT01250652 - Levocetirizine Plus Bed-Time Hydroxyzine in the Management of Corticodependent Chronic Urticaria Versus Levocetirizine Alone in High Doses Phase 4
Completed NCT01111136 - Stress Intervention for Chronic Urticaria N/A
Recruiting NCT01425593 - T Cell Function in Chronic Idiopathic Urticaria N/A
Completed NCT00737451 - Association of Thyroid Autoimmunity and Chronic Urticaria N/A
Completed NCT00619801 - Safety Study of Levocetirizine Dihydrochloride Oral Liquid Formulation in Children Aged 1 to Less Than 6 Years Suffering From Allergic Rhinitis or Chronic Urticaria of Unknown Origin Phase 3
Completed NCT00628108 - Safety Study of Levocetirizine Dihydrochloride Oral Liquid Formulation in Children Aged 6 Months to 11 Months Phase 3
Completed NCT01284426 - Natural History of Chronic Urticaria N/A